Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EPGL.... Read the latest news.... Very impressive .
Cord Blood America Announces 2013 First Quarter Financial Results
LAS VEGAS, May 15, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the quarter ended March 31, 2013.
First Quarter 2013 Highlights From Continuing Operations
Recurring revenues increased approximately 7% for the three months ended March 31, 2013 to $740,124.
Cash provided by operations totaled $128,970 in the first quarter. This represents 68% of the total full year cash generated in 2012 of $190,323.
EBITDA for the quarter increased 587% to $99,985 from $14,542 in the year ago period.
SG&A decreased 11% to $1.11 million from $1.24 million in the year ago period.
Our cash balance increased 40% to $369,186 compared to the same period a year ago.
Rumored rs
Amazing technology! EPGL is going to revolutionize our technology.
EPGL Medical Invents Self Powered Contact Lenses for Medical and Consumer Applications
IRVINE, Calif., July 29, 2013 /PRNewswire/ -- EP Global Communications, Inc. and EPGL Medical (the Company), (OTC-PINK: EPGL) announced today that Company engineers have invented the world's first self powered, self contained, power source for contact lenses. The power supply comes from within the lenses and is self perpetuating day or night. "Using cutting edge technology, EPGL has invented a self perpetuating power source for lenses which does not require external energy such as RF," said David Markus PhD. "The market for contact lenses as information data display devices is just beginning and will be a natural extension of new wearable data devices such as Google Glass." EPGL intends to license the new technology to companies who are developing data display for contact lenses.
Researchers are now designing applications for use in contact lenses for both health care and consumer needs. One use of powered contact lenses being investigated is for displaying data in real-time to the lenses wearer about medical data such as their blood sugar level, oxygen level, heart rate, EKG and many other possible medical applications. Powered contact lenses are also being looked into as delivery devices for drugs and other therapeutic applications.
In the consumer electronics market, powered contact lenses have promise to display data from the Internet directly into the wearer's field of vision real-time. "Imagine being able to have telescopic vision on demand or microscopic vision. The applications for what people could want to have displayed in their vision at the blink of an eye are virtually endless," said Michael Hayes, President of EPGL Medical. "We intend to license the new power technology for those applications because the future market is obviously significant in size and scope."
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with a world-class team of doctors and scientists on board. The Company is currently marketing its first FDA cleared device with several additional "smart" medical devices under development. The Company is the owner of the cutting edge technological platform for medical device development called "Topspin."
SOURCE EP Global Communications, Inc.
Copyright 2013 PR Newswire
EPGL Medical Invents Self Powered Contact Lenses for Medical and Consumer Applications
IRVINE, Calif., July 29, 2013 /PRNewswire/ -- EP Global Communications, Inc. and EPGL Medical (the Company), (OTC-PINK: EPGL) announced today that Company engineers have invented the world's first self powered, self contained, power source for contact lenses. The power supply comes from within the lenses and is self perpetuating day or night. "Using cutting edge technology, EPGL has invented a self perpetuating power source for lenses which does not require external energy such as RF," said David Markus PhD. "The market for contact lenses as information data display devices is just beginning and will be a natural extension of new wearable data devices such as Google Glass." EPGL intends to license the new technology to companies who are developing data display for contact lenses.
Researchers are now designing applications for use in contact lenses for both health care and consumer needs. One use of powered contact lenses being investigated is for displaying data in real-time to the lenses wearer about medical data such as their blood sugar level, oxygen level, heart rate, EKG and many other possible medical applications. Powered contact lenses are also being looked into as delivery devices for drugs and other therapeutic applications.
In the consumer electronics market, powered contact lenses have promise to display data from the Internet directly into the wearer's field of vision real-time. "Imagine being able to have telescopic vision on demand or microscopic vision. The applications for what people could want to have displayed in their vision at the blink of an eye are virtually endless," said Michael Hayes, President of EPGL Medical. "We intend to license the new power technology for those applications because the future market is obviously significant in size and scope."
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with a world-class team of doctors and scientists on board. The Company is currently marketing its first FDA cleared device with several additional "smart" medical devices under development. The Company is the owner of the cutting edge technological platform for medical device development called "Topspin."
SOURCE EP Global Communications, Inc.
Copyright 2013 PR Newswire
Only over two months ago????? That is current. Companies do not post every week for updates. CBAI is $$$$$
Cord Blood America Announces 2013 First Quarter Financial Results
LAS VEGAS, May 15, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the quarter ended March 31, 2013.
First Quarter 2013 Highlights From Continuing Operations
Recurring revenues increased approximately 7% for the three months ended March 31, 2013 to $740,124.
Cash provided by operations totaled $128,970 in the first quarter. This represents 68% of the total full year cash generated in 2012 of $190,323.
EBITDA for the quarter increased 587% to $99,985 from $14,542 in the year ago period.
SG&A decreased 11% to $1.11 million from $1.24 million in the year ago period.
Our cash balance increased 40% to $369,186 compared to the same period a year ago.
Joseph Vicente, President of Cord Blood America, Inc. commented "During the quarter, Biocordcell Argentina (Bio), made investments in lab related processes, causing increased costs which we expect to be primarily one-time charges. The Company believes these investments will help support future growth. We remain focused on reducing our corporate costs, which were down 11%, despite the increased costs from Bio in the first quarter. We also remain committed to ensuring that incremental revenue growth meets a corresponding increase in profitability, as the Company will not add to its debt under the current conditions. We remain bullish on the industry and our prospects for future growth."
For the three months ended March 31, 2013, total revenue increased to approximately $1.45 million from $1.43 million compared to the year ago period. Recurring revenues increased approximately 7% while tissue related sales increased at 31%, offset by an 11% decrease in processing fees.
Massive buying on the ask! EPGL is going up fast. $$$$$$
EPGL Medical Invents Self Powered Contact Lenses for Medical and Consumer Applications
IRVINE, Calif., July 29, 2013 /PRNewswire/ -- EP Global Communications, Inc. and EPGL Medical (the Company), (OTC-PINK: EPGL) announced today that Company engineers have invented the world's first self powered, self contained, power source for contact lenses. The power supply comes from within the lenses and is self perpetuating day or night. "Using cutting edge technology, EPGL has invented a self perpetuating power source for lenses which does not require external energy such as RF," said David Markus PhD. "The market for contact lenses as information data display devices is just beginning and will be a natural extension of new wearable data devices such as Google Glass." EPGL intends to license the new technology to companies who are developing data display for contact lenses.
Researchers are now designing applications for use in contact lenses for both health care and consumer needs. One use of powered contact lenses being investigated is for displaying data in real-time to the lenses wearer about medical data such as their blood sugar level, oxygen level, heart rate, EKG and many other possible medical applications. Powered contact lenses are also being looked into as delivery devices for drugs and other therapeutic applications.
In the consumer electronics market, powered contact lenses have promise to display data from the Internet directly into the wearer's field of vision real-time. "Imagine being able to have telescopic vision on demand or microscopic vision. The applications for what people could want to have displayed in their vision at the blink of an eye are virtually endless," said Michael Hayes, President of EPGL Medical. "We intend to license the new power technology for those applications because the future market is obviously significant in size and scope."
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with a world-class team of doctors and scientists on board. The Company is currently marketing its first FDA cleared device with several additional "smart" medical devices under development. The Company is the owner of the cutting edge technological platform for medical device development called "Topspin."
SOURCE EP Global Communications, Inc.
Copyright 2013 PR Newswire
Cord Blood America Announces 2013 First Quarter Financial Results
LAS VEGAS, May 15, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the quarter ended March 31, 2013.
First Quarter 2013 Highlights From Continuing Operations
Recurring revenues increased approximately 7% for the three months ended March 31, 2013 to $740,124.
Cash provided by operations totaled $128,970 in the first quarter. This represents 68% of the total full year cash generated in 2012 of $190,323.
EBITDA for the quarter increased 587% to $99,985 from $14,542 in the year ago period.
SG&A decreased 11% to $1.11 million from $1.24 million in the year ago period.
Our cash balance increased 40% to $369,186 compared to the same period a year ago.
Elite Pharmaceuticals Awarded Second U.S. Patent for Abuse Resistant Drug Formulation
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the issuance of U.S. Patent No. 8,425,933 entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" by the United States Patent and Trademark Office. This is the second issued U.S. patent covering Elite's abuse resistant technology for opioid products. Elite has additional patents pending in the U.S., Canada and Europe.
"We are pleased to receive this second abuse resistant patent. The recent guidances and actions by the FDA related to extended release opioids and specifically oxycodone demonstrates the FDA support for abuse resistant technologies. Opioid products incorporating abuse resistant technologies have become a public health priority and these recent actions appear to be a major step towards the FDA eventually requiring that all extended release opioids utilize these technologies. This validates our approach and we believe substantially increases the value of our intellectual property and the abuse resistant products in our pipeline," said Jerry Treppel, Elite's Chairman and CEO.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has three commercial products currently being sold, three additional products approved and soon to be launched, and one additional product pending approval by the FDA. Elite's lead pipeline products include abuse resistant opioids utilizing the Company's patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also provides contract manufacturing for Actavis and Ascend Laboratories (previously a subsidiary of ThePharmaNetwork and now a subsidiary of Alkem Laboratories Ltd.) and has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
Cord Blood America Announces 2013 First Quarter Financial Results
LAS VEGAS, May 15, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the quarter ended March 31, 2013.
First Quarter 2013 Highlights From Continuing Operations
Recurring revenues increased approximately 7% for the three months ended March 31, 2013 to $740,124.
Cash provided by operations totaled $128,970 in the first quarter. This represents 68% of the total full year cash generated in 2012 of $190,323.
EBITDA for the quarter increased 587% to $99,985 from $14,542 in the year ago period.
SG&A decreased 11% to $1.11 million from $1.24 million in the year ago period.
Our cash balance increased 40% to $369,186 compared to the same period a year ago.
Nice try.... CBAI is $$$$$$
EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
IRVINE, Jun 18, 2013 (GLOBE NEWSWIRE via COMTEX) - via PRWEB - EP Global Communications, Inc. (the Company), (Stock Ticker: EPGL) EPGL Medical Sciences, is pleased to announce several new devices resulting from the TopSpin technology recently announced. Many of these devices have not been revealed before today. To Compliment the MPDD, the new MPTT will be first to become a prototype this fall and new FDA 510k and PMA Applications are being prepared for filing during 3rd and 4th Quarters. EPGL has filed patents and owns unique Intellectual Property for each of the following new smart medical devices:
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
Several more devices beyond this list will be revealed in coming months by the Company. This represents the beginning for EPGL technological development.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
Cord Blood America Announces 2013 First Quarter Financial Results
LAS VEGAS, May 15, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the quarter ended March 31, 2013.
First Quarter 2013 Highlights From Continuing Operations
Recurring revenues increased approximately 7% for the three months ended March 31, 2013 to $740,124.
Cash provided by operations totaled $128,970 in the first quarter. This represents 68% of the total full year cash generated in 2012 of $190,323.
EBITDA for the quarter increased 587% to $99,985 from $14,542 in the year ago period.
SG&A decreased 11% to $1.11 million from $1.24 million in the year ago period.
Our cash balance increased 40% to $369,186 compared to the same period a year ago.
Excellent day
Cord Blood America Announces 2013 First Quarter Financial Results
LAS VEGAS, May 15, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the quarter ended March 31, 2013.
First Quarter 2013 Highlights From Continuing Operations
Recurring revenues increased approximately 7% for the three months ended March 31, 2013 to $740,124.
Cash provided by operations totaled $128,970 in the first quarter. This represents 68% of the total full year cash generated in 2012 of $190,323.
EBITDA for the quarter increased 587% to $99,985 from $14,542 in the year ago period.
SG&A decreased 11% to $1.11 million from $1.24 million in the year ago period.
Our cash balance increased 40% to $369,186 compared to the same period a year ago.
Bayside Corp. Announces Joint Venture with C-Trade Group, for Heavy Fuel Oil Exports
DALLAS, July 24, 2013 /PRNewswire/ -- Bayside Corp. (OTC: BYSD) an energy exploration, development and production company today announced a joint venture with C-Trade Group, Inc. a petroleum logistics trade and finance company for heavy fuel oil exports.
Under the agreement C-Trade Group, Inc. will help to provide financing and contract support in the form of monthly bank guarantees in the amount of $160,500,000 for international heavy fuel oil exports.
Additionally, the C-Trade Group and Bayside Corp. have previously worked together successfully under a joint venture financing agreement for the redeveloping of existing oil fields using today's technology to restore and access more production from wells that were drilled 30 plus years ago.
Gordon Johnson was quoted as saying, "We are pleased to be able to partner with the C-Trade Group once more to continue our efforts to expand our revenue base."
About Bayside
Bayside Corporation is an energy exploration, development and production company building oil & gas reserves and production in some of the most prolific hydrocarbon bearing regions of the United States. The Company specializes in the business of reworking & re-completing 'marginal' oil & gas wells located in the thousands of mature oil & gas producing fields across much of the United States.
For additional information on the Company visit our website at: http://baysidepetroleum.com/
I agree Coci. Walgreens is a huge company, which validates MDIN as a legitimate company with solid products.
Northstar's products to be carried by top online retailers, drugstore.com and Walgreen.com as part of its online sales strategy
HOLBROOK, N.Y., June 11, 2013 /PRNewswire/ -- Northstar Global Business Services, Inc. Symbol (OTCPink: MDIN), today announced it has started a major expansion of it's online sales, signing deals with several web based retailers, and the websites of several current retail distributors to vastly increase its web presence and sales numbers.
It's no secret that online sales are a key part of every manufacturer's business, and Northstar's online sales numbers have been growing exponentially ever since they first launched their product line. As the company anxiously awaits rollout of its products into "Big box" retailers nationwide and globally, they have started executing their online sales and marketing strategy by signing distribution deals that will allow several of the largest online retailers to pick up their product line gaining massive exposure for Northstar in the months to come.
The online, health and beauty retail industry is fiercely competitive, so purchasing and warehousing product, and then utilizing precious web traffic promoting it is sometimes even riskier than putting product on the physical shelves. Northstar's advantage in brick-and-mortar retail distribution is that the company has a long track record of sales with most major retailers from 1998 to 2009. Retailers know what they should expect, but as far as online sales are concerned, Snorenz is as much a risk as any new product. Fortunately, the company's success with it's own online sales, and with the small amount of retail locations already rolled out, is giving the confidence to retailers that they. Currently, Drugstore.com and Walgreens.com are on board and preparing to receive shipments of the product, so that they are well stocked when the product appears on their website's approximately thirty days from now, but Northstar is confident that all of their current wholesale customers, and those who are not yet customers, will want to distribute the company's products online as well.
"We are very happy that Drugstore.com and Walgreens.com are the first to pick up the product online. We know how well Snorenz sells online, and we know with the lower overhead that the internet offers, online sales will be very profitable for them," said Nicholas Chieco, Northstar's CEO.
With major retail distribution expected to be in full swing by the end of July, the rapidly expanding online distribution model will also be applied to Northstar's other products increasing next quarters revenue projections by almost double.
About Northstar
Northstar Global Business Services is dedicated to producing the best alternative healthcare products. The most popular products in Northstar's arsenal are Snorenz©, a patented spray for snoring relief, Stem-Intense, a unique stem cell replacement therapy supplement, and Health-Enrich for pets, an exciting new supplement that promotes pet health and can help relieve many problems experienced by aging pets. Most of the company's products use a proprietary or patented formula, spray delivery system, or ingredients, and have received very positive consumer reviews all over the world, selling millions of units from 1996 to the present. For more information please call Jennifer at 877-571-4387 or email investor@northstarbb.com
About Drugstore.com®
Drugstore.com is a leading online provider of health, beauty, vision, and pharmacy products, offering a wide assortment of more than 75,000 products at competitive prices while providing a convenient, private, and informative shopping experience. www.drugstore.com
About Walgreens.com®
Walgreens.com is America's online pharmacy and has been serving its customers' needs since 1901. Shop online at www.Walgreens.com to refill prescriptions, schedule flu shots, print photos and much more.
Northstar's products to be carried by top online retailers, drugstore.com and Walgreen.com as part of its online sales strategy
HOLBROOK, N.Y., June 11, 2013 /PRNewswire/ -- Northstar Global Business Services, Inc. Symbol (OTCPink: MDIN), today announced it has started a major expansion of it's online sales, signing deals with several web based retailers, and the websites of several current retail distributors to vastly increase its web presence and sales numbers.
It's no secret that online sales are a key part of every manufacturer's business, and Northstar's online sales numbers have been growing exponentially ever since they first launched their product line. As the company anxiously awaits rollout of its products into "Big box" retailers nationwide and globally, they have started executing their online sales and marketing strategy by signing distribution deals that will allow several of the largest online retailers to pick up their product line gaining massive exposure for Northstar in the months to come.
The online, health and beauty retail industry is fiercely competitive, so purchasing and warehousing product, and then utilizing precious web traffic promoting it is sometimes even riskier than putting product on the physical shelves. Northstar's advantage in brick-and-mortar retail distribution is that the company has a long track record of sales with most major retailers from 1998 to 2009. Retailers know what they should expect, but as far as online sales are concerned, Snorenz is as much a risk as any new product. Fortunately, the company's success with it's own online sales, and with the small amount of retail locations already rolled out, is giving the confidence to retailers that they. Currently, Drugstore.com and Walgreens.com are on board and preparing to receive shipments of the product, so that they are well stocked when the product appears on their website's approximately thirty days from now, but Northstar is confident that all of their current wholesale customers, and those who are not yet customers, will want to distribute the company's products online as well.
"We are very happy that Drugstore.com and Walgreens.com are the first to pick up the product online. We know how well Snorenz sells online, and we know with the lower overhead that the internet offers, online sales will be very profitable for them," said Nicholas Chieco, Northstar's CEO.
With major retail distribution expected to be in full swing by the end of July, the rapidly expanding online distribution model will also be applied to Northstar's other products increasing next quarters revenue projections by almost double.
About Northstar
Northstar Global Business Services is dedicated to producing the best alternative healthcare products. The most popular products in Northstar's arsenal are Snorenz©, a patented spray for snoring relief, Stem-Intense, a unique stem cell replacement therapy supplement, and Health-Enrich for pets, an exciting new supplement that promotes pet health and can help relieve many problems experienced by aging pets. Most of the company's products use a proprietary or patented formula, spray delivery system, or ingredients, and have received very positive consumer reviews all over the world, selling millions of units from 1996 to the present. For more information please call Jennifer at 877-571-4387 or email investor@northstarbb.com
About Drugstore.com®
Drugstore.com is a leading online provider of health, beauty, vision, and pharmacy products, offering a wide assortment of more than 75,000 products at competitive prices while providing a convenient, private, and informative shopping experience. www.drugstore.com
About Walgreens.com®
Walgreens.com is America's online pharmacy and has been serving its customers' needs since 1901. Shop online at www.Walgreens.com to refill prescriptions, schedule flu shots, print photos and much more.
EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
IRVINE, Jun 18, 2013 (GLOBE NEWSWIRE via COMTEX) - via PRWEB - EP Global Communications, Inc. (the Company), (Stock Ticker: EPGL) EPGL Medical Sciences, is pleased to announce several new devices resulting from the TopSpin technology recently announced. Many of these devices have not been revealed before today. To Compliment the MPDD, the new MPTT will be first to become a prototype this fall and new FDA 510k and PMA Applications are being prepared for filing during 3rd and 4th Quarters. EPGL has filed patents and owns unique Intellectual Property for each of the following new smart medical devices:
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
Several more devices beyond this list will be revealed in coming months by the Company. This represents the beginning for EPGL technological development.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has three commercial products currently being sold, three additional products approved and soon to be launched, and one additional product pending approval by the FDA. Elite's lead pipeline products include abuse resistant opioids utilizing the Company's patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also provides contract manufacturing for Actavis and Ascend Laboratories (previously a subsidiary of ThePharmaNetwork and now a subsidiary of Alkem Laboratories Ltd.) and has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
Elite Pharmaceuticals Awarded Second U.S. Patent for Abuse Resistant Drug Formulation
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the issuance of U.S. Patent No. 8,425,933 entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" by the United States Patent and Trademark Office. This is the second issued U.S. patent covering Elite's abuse resistant technology for opioid products. Elite has additional patents pending in the U.S., Canada and Europe.
"We are pleased to receive this second abuse resistant patent. The recent guidances and actions by the FDA related to extended release opioids and specifically oxycodone demonstrates the FDA support for abuse resistant technologies. Opioid products incorporating abuse resistant technologies have become a public health priority and these recent actions appear to be a major step towards the FDA eventually requiring that all extended release opioids utilize these technologies. This validates our approach and we believe substantially increases the value of our intellectual property and the abuse resistant products in our pipeline," said Jerry Treppel, Elite's Chairman and CEO.
By Your StandarD.... :)
Elite Pharmaceuticals Awarded Second U.S. Patent for Abuse Resistant Drug Formulation
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the issuance of U.S. Patent No. 8,425,933 entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" by the United States Patent and Trademark Office. This is the second issued U.S. patent covering Elite's abuse resistant technology for opioid products. Elite has additional patents pending in the U.S., Canada and Europe.
"We are pleased to receive this second abuse resistant patent. The recent guidances and actions by the FDA related to extended release opioids and specifically oxycodone demonstrates the FDA support for abuse resistant technologies. Opioid products incorporating abuse resistant technologies have become a public health priority and these recent actions appear to be a major step towards the FDA eventually requiring that all extended release opioids utilize these technologies. This validates our approach and we believe substantially increases the value of our intellectual property and the abuse resistant products in our pipeline," said Jerry Treppel, Elite's Chairman and CEO.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has three commercial products currently being sold, three additional products approved and soon to be launched, and one additional product pending approval by the FDA. Elite's lead pipeline products include abuse resistant opioids utilizing the Company's patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also provides contract manufacturing for Actavis and Ascend Laboratories (previously a subsidiary of ThePharmaNetwork and now a subsidiary of Alkem Laboratories Ltd.) and has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
I will hold my shares of ELTP. Thank you though for your advice.
I'm going to keep my shares of CBAI.... $$$$$ thank you though for your advice.
EPGL is $$$$$$$$.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
Several more devices beyond this list will be revealed in coming months by the Company. This represents the beginning for EPGL technological development.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
IRVINE, Jun 18, 2013 (GLOBE NEWSWIRE via COMTEX) - via PRWEB - EP Global Communications, Inc. (the Company), (Stock Ticker: EPGL) EPGL Medical Sciences, is pleased to announce several new devices resulting from the TopSpin technology recently announced. Many of these devices have not been revealed before today. To Compliment the MPDD, the new MPTT will be first to become a prototype this fall and new FDA 510k and PMA Applications are being prepared for filing during 3rd and 4th Quarters. EPGL has filed patents and owns unique Intellectual Property for each of the following new smart medical devices:
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
I think the 160,000 shares bought made up for it. :)
MediSwipe Inc. Announces New Two Year National Distribution Agreement for Chillo Energy Drink and C+ Swiss Hemp Teas to Medic...
LOS ANGELES, CA--(Marketwired - July 17, 2013) - MediSwipe Inc. (www.MediSwipe.com) (OTCQB: MWIP), a data management solutions company for the medicinal marijuana and health care industry, today announced that the Company has agreed to a new two (2) year licensing agreement with Chill Drinks LLC for the popular hemp based energy drink "CHILLO" and C+ Swiss Hemp Tea. The terms of the agreement will allow MediSwipe to remain the exclusive provider of the popular drinks to all medical dispensaries, pharmacies, approved retail locations, Amazon and e-commerce sites. The amended 2 year agreement also encompasses Chillo merchandising rights including T-shirts, hats, glasses, etc. as additional retail revenue streams for MediSwipe.
"We new we had an excellent opportunity and the right network to make this work out of the gate. Although we didn't plan to be in the beverage industry, we believe these drinks fit within our health and wellness division and provide a unique and synergistic relationship because of the Hemp and medicinal benefits that fit our customer base. Chillo and C+ Swiss have immediately opened doors to our patient database services and merchant processing applications allowing MediSwipe to further cement or relationships within the sector and rely on several forms of developing revenue streams," stated B. Michael Friedman, CEO of MediSwipe Inc.
CHILLO, with its distinct trademark orange can, carries the chill of hemp seed extract with the added punch and perfect blend of caffeine, vitamins B6 and B12 for the ultimate drink experience.
The popular energy drink is now for sale with the world's largest online retailer on Amazon.com Marketplace exclusively through MediSwipe. The Company also offers its brand of hemp-based tea C+ Swiss. C+SWISS is popularly known as the original hemp based ice tea approved for sale in the United States, with distribution already in Whole Foods and major markets nationally. The hemp based drink comes in eco-friendly, recyclable packaging that stands out to the health conscious target customer. C+SWISS contains all natural ingredients including non-gmo beet sugar, concentrated lemon juice, hemp seed extract, black tea extract, and natural flavoring consisting of fruit and plant extracts.
Both brands are available in medical dispensaries and select retail locations across the country or exclusively through MediSwipe by calling 248.262.6850. If you are interested in becoming a distributor, please contact MediSwipe through email at info@MediSwipe.com.
Visit the Company on Facebook, and for every 420th "Like" the Company will give away a free Chillo and C+ Swiss gift pack to that lucky friend.
About MediSwipe Inc.
MediSwipe Inc. (www.MediSwipe.com) provides innovative patient solutions for electronically processing transactions within the healthcare industry. MediSwipe provides terminal-based service packages and integrated Web Portal add-ons for physicians, clinics, hospitals and medical dispensaries that include: digital patient records, Electronic Referrals, Credit/Debit Card merchant services, Check Guarantee and Accounts Receivable Financing.
My investment group is still holding on to CBMC. Thank you FROGGER for your help.
About: Micro Imaging Technology, Inc.
Micro Imaging Technology, Inc. is a California-based public company that is also registered to do business under the name Micro Identification Technologies. MIT has developed and patented the MIT-1000, a stand-alone, optically-based, software driven system that can detect pathogenic bacteria and complete an identification test, after culturing, in less than three (3) minutes (average) at the lowest cost per test when compared to any other conventional method. It does not rely on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis. The process requires only clean particle-free water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually -- with food safety accounting for over $3.5 billion, which is expected to surpass $4.7 billion by 2015 according to BCC Research. In addition, the recently passed "New" U.S. Food Safety Bill is expected to further accelerate the current annual growth rate of 6.6 percent.
You can find more information about our company and about Micro Identification Technologies™. Please visit our newly enhanced website at www.micro-identification.com.
Elite Pharmaceuticals Awarded Second U.S. Patent for Abuse Resistant Drug Formulation
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the issuance of U.S. Patent No. 8,425,933 entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" by the United States Patent and Trademark Office. This is the second issued U.S. patent covering Elite's abuse resistant technology for opioid products. Elite has additional patents pending in the U.S., Canada and Europe.
"We are pleased to receive this second abuse resistant patent. The recent guidances and actions by the FDA related to extended release opioids and specifically oxycodone demonstrates the FDA support for abuse resistant technologies. Opioid products incorporating abuse resistant technologies have become a public health priority and these recent actions appear to be a major step towards the FDA eventually requiring that all extended release opioids utilize these technologies. This validates our approach and we believe substantially increases the value of our intellectual property and the abuse resistant products in our pipeline," said Jerry Treppel, Elite's Chairman and CEO.
June 13th 2013... MediSwipe Inc. Announces First eCommerce Sales of Hemp Based Energy Drink "Chillo" on Amazon.com
LOS ANGELES, June 13, 2013 /PRNewswire/ -- MediSwipe Inc. (www.MediSwipe.com) (OTCQB: MWIP), a data management solutions company for the medicinal marijuana and health care industry, today announced that the Company's popular hemp based energy drink "CHILLO" is now for sale with the world's largest online retailer on Amazon.com Marketplace. With the trusted Amazon platform and fulfillment services, MediSwipe expects to experience a surge in orders of the beverage through ecommerce sales as the products profit from enhanced visibility within the Amazon catalog.
"Chillo is a one of a kind product, and can only benefit from being placed in front of tens of millions of potential customers. Amazon.com offers an opportunity to reach a niche market as we can now service customers across North America and abroad. As we expand the brand globally, we are proud to partner with the largest and most successful online marketplace around the world," stated MediSwipe CEO, B. Michael Friedman.
With the dramatic orange color and flavor of CHILLO, and added benefits of hemp, vitamins and caffeine, we are pleased to be able to deliver the product through Amazon.com for those who are not able to access it through our retail network," stated B. Michael Friedman for MediSwipe.
The Company has also announced plans to launch additional online marketing campaigns through its Facebook site for both "Chillo" and C+ Swiss Tea. Starting today, for every 420th "Like" to the Company's Facebook page, the Company will give away a free Chillo and C+Swiss gift pack to that lucky friend.
CHILLO, with its distinct trademark orange can, carries the chill of hemp seed extract with the added punch and perfect blend of caffeine, vitamins B6 and B12 for the ultimate drink experience. Both Chillo and C+ Swiss Hemp Tea are available in dispensaries and select locations across the country, and may be ordered exclusively through MediSwipe by calling 248.262.6850 or through email at info@MediSwipe.com.
About MediSwipe Inc.
MediSwipe Inc. (www.MediSwipe.com) provides innovative patient solutions for electronically processing transactions within the healthcare industry. MediSwipe provides terminal-based service packages and integrated Web Portal add-ons for physicians, clinics, hospitals and medical dispensaries that include: digital patient records, Electronic Referrals, Credit/Debit Card merchant services, Check Guarantee and Accounts Receivable Financing.
One month news is considered old???? Seriously???? Are you expecting news from a company every 30 days??????